Millions of ECGs are performed every week, however, for decades these tests have largely remained unchanged. Conventional ECGs are easy and quick to perform, but unfortunately do not detect most heart disease conditions.
Artificial Intelligence-Enhanced Electrocardiography (AI-ECG) is set to transform cardiovascular medicine. AI-ECG allows previously unseen disease to be identified and radically expands the clinical usefulness of an ECG.
Known as the silent killer, heart attacks can occur unexpectedly, and heart disease symptoms often do not appear until an acute stage.*
AI-ECG provides frontline healthcare with more effective diagnoses and referrals, ensuring earlier treatment and better outcomes.
1 in 5 heart attacks are silent – the damage is done, but the person is not aware of it.
19.9 million deaths from cardiovascular disease (CVD) in 2021***
* Center for Disease Control and Prevention. Heart Disease Facts
** The Center for Advancing Health (CFAH). Heart Disease Statistics in the US (2024 Update)
*** American Heart Association. 2024 Heart Disease and Stroke Statistics Update Fact Sheet
HeartSciences is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one
November 13, 2024 Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence
Publications Abstract Background Recent guidelines propose N-terminal pro-B-type natriuretic peptide (NT-proBNP) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes mellitus (T2DM).
Publications Originally published 29 Dec 2023 https://doi.org/10.1161/JAHA.123. 31671 Journal of the American Heart Association. 2024;13:e031671 Link to article: Quantitative Prediction of Right Ventricular Size and Function From the ECG | Journal
Publications Joshua Lampert, Akhil Vaid, William Whang, Jacob Koruth, Marc A. Miller, Marie-Noelle Langan, Daniel Musikantow, Mohit Turagam, Abhishek Maan, Iwanari Kawamura, Srinivas Dukkipati, Girish N. Nadkarni, and Vivek Y. Reddy Abstract Background Premature ventricular complexes (PVCs) are prevalent and, although often
HeartSciences’ AI-ECG products are currently in development and not commercially available in the United States.
wavECG and wavEKG are trademarks of HeartSciences.
MV-WBSTE-002 Rev A
